Skip to Main Content

While biotech’s fortunes have soured on Wall Street this week, the sector’s biggest IPO of the year went off without a hitch Thursday, suggesting investors haven’t lost their appetite for high-risk, high-reward science.

Allogene Therapeutics (ALLO), a company focused on cancer, raised more than $300 million in its market debut, securing a valuation of roughly $2.5 billion. And the company got a warm reception in early trading, rising more than 30 percent by mid-morning.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!